Avenue Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OID
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Avenue Therapeutics, Inc.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Avenue Therapeutics, Inc. as of December 31, 2024.
OID
Ikarian Capital, LLC and Neil Shahrestani have jointly disclosed a passive 6.8% beneficial ownership stake in Avenue Therapeutics, Inc., holding 140,000 shares of common stock.